E
Summit Therapeutics Inc.
SMMT
$20.46
$1.668.83%
E
Sell
5/22/2023Downgrade
Summit Therapeutics Inc. (SMMT) was downgraded to E+ from D- on 5/22/2023 due to a significant decline in the total return index, growth index and valuation index. Earnings per share declined from -$0.0707 to -$1.4342, operating cash flow declined 352.96% from $5.19M to -$13.13M, and EBIT declined 24% from -$13.1M to -$16.24M.
Summit Therapeutics Inc. (SMMT) was downgraded to E+ from D- on 5/22/2023 due to a significant decline in the total return index, growth index and valuation index. Earnings per share declined from -$0.0707 to -$1.4342, operating cash flow declined 352.96% from $5.19M to -$13.13M, and EBIT declined 24% from -$13.1M to -$16.24M.
D
Sell
3/14/2023Downgrade
Summit Therapeutics Inc. (SMMT) was downgraded to D- from D on 3/14/2023 due to a decline in the solvency index. Debt to equity increased from 0.01 to 4.07.
Summit Therapeutics Inc. (SMMT) was downgraded to D- from D on 3/14/2023 due to a decline in the solvency index. Debt to equity increased from 0.01 to 4.07.
D
Sell
2/9/2023Upgraded
Summit Therapeutics Inc. (SMMT) was upgraded to D from E+ on 2/9/2023 due to an increase in the valuation index.
Summit Therapeutics Inc. (SMMT) was upgraded to D from E+ on 2/9/2023 due to an increase in the valuation index.
E
Sell
2/8/2023Downgrade
Summit Therapeutics Inc. (SMMT) was downgraded to E+ from D on 2/8/2023 due to a decline in the valuation index and volatility index.
Summit Therapeutics Inc. (SMMT) was downgraded to E+ from D on 2/8/2023 due to a decline in the valuation index and volatility index.
D
Sell
5/31/2022Upgraded
Summit Therapeutics Inc. (SMMT) was upgraded to D from D- on 5/31/2022 due to an increase in the volatility index.
Summit Therapeutics Inc. (SMMT) was upgraded to D from D- on 5/31/2022 due to an increase in the volatility index.
D
Sell
5/13/2022Downgrade
Summit Therapeutics Inc. (SMMT) was downgraded to D- from D on 5/13/2022 due to a decline in the solvency index, total return index and volatility index. Debt to equity increased from 0.01 to 0.4.
Summit Therapeutics Inc. (SMMT) was downgraded to D- from D on 5/13/2022 due to a decline in the solvency index, total return index and volatility index. Debt to equity increased from 0.01 to 0.4.
D
Sell
5/5/2022Upgraded
Summit Therapeutics Inc. (SMMT) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
Summit Therapeutics Inc. (SMMT) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
D
Sell
4/20/2022Downgrade
Summit Therapeutics Inc. (SMMT) was downgraded to D- from D on 4/20/2022 due to a significant decline in the growth index, solvency index and total return index. Total revenue declined 80.83% from $1.31M to $251, earnings per share declined from -$0.2011 to -$0.2801, and EBIT declined 33.67% from -$19.49M to -$26.05M.
Summit Therapeutics Inc. (SMMT) was downgraded to D- from D on 4/20/2022 due to a significant decline in the growth index, solvency index and total return index. Total revenue declined 80.83% from $1.31M to $251, earnings per share declined from -$0.2011 to -$0.2801, and EBIT declined 33.67% from -$19.49M to -$26.05M.
D
Sell
3/4/2022Downgrade
Summit Therapeutics Inc. (SMMT) was downgraded to D from D+ on 3/4/2022 due to a decline in the volatility index and total return index.
Summit Therapeutics Inc. (SMMT) was downgraded to D from D+ on 3/4/2022 due to a decline in the volatility index and total return index.
D
Sell
12/23/2021Upgraded
Summit Therapeutics Inc. (SMMT) was upgraded to D+ from D on 12/23/2021 due to an increase in the valuation index.
Summit Therapeutics Inc. (SMMT) was upgraded to D+ from D on 12/23/2021 due to an increase in the valuation index.
D
Sell
11/16/2021Upgraded
Summit Therapeutics Inc. (SMMT) was upgraded to D from D- on 11/16/2021 due to a significant increase in the growth index and total return index. Total revenue increased 2,196.49% from $57 to $1.31M, earnings per share increased from -$0.27 to -$0.2011, and EBIT increased 17.88% from -$23.73M to -$19.49M.
Summit Therapeutics Inc. (SMMT) was upgraded to D from D- on 11/16/2021 due to a significant increase in the growth index and total return index. Total revenue increased 2,196.49% from $57 to $1.31M, earnings per share increased from -$0.27 to -$0.2011, and EBIT increased 17.88% from -$23.73M to -$19.49M.
D
Sell
11/8/2021Downgrade
Summit Therapeutics Inc. (SMMT) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the growth index. Total revenue declined 70.31% from $192 to $57, EBIT declined 40.22% from -$16.92M to -$23.73M, and earnings per share declined from -$0.2112 to -$0.27.
Summit Therapeutics Inc. (SMMT) was downgraded to D- from D on 11/8/2021 due to a noticeable decline in the growth index. Total revenue declined 70.31% from $192 to $57, EBIT declined 40.22% from -$16.92M to -$23.73M, and earnings per share declined from -$0.2112 to -$0.27.
D
Sell
9/25/2020None
Summit Therapeutics Inc. (SMMT) was downgraded to D from U on 09/25/2020.
Summit Therapeutics Inc. (SMMT) was downgraded to D from U on 09/25/2020.
NASDAQ
04/02/2025 4:00PM Eastern
Quotes delayed
